Clinical trials: Metformin, completed
Type 2 Diabetes Mellitus (T2DM)
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
To assess the relative bioavailability of dapagliflozin and metformin from the two FDC formulations, comprised of 10 mg dapagliflozin and 1000 mg metformin XR, relative to coadministration of a dapagliflozin 10 mg tablet and 2 x…
- Trial name
- NCT01002807
- Testing
- Dapagliflozin, Metformin XR, Glucophage
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.
To assess the bioequivalence between dapagliflozin/metformin XR FDC tablet and co-administration of dapagliflozin and metformin XR tablets.
- Trial name
- NCT04856007
- Testing
- Dapagliflozin/metformin XR FDC 5/500 mg, Dapagliflozin/metformin XR FDC 10/1000 mg, Dapagliflozin 5 mg + Metformin 500 mg XR
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of Empagliflozin and metformin compared to the administration of single tablets (Empagliflozin and metformin ) in Chinese subjects.
- Trial name
- NCT02102932
- Testing
- 5 mg empagliflozin/850 mg metformin FDC, 12.5 mg empagliflozin, 850 mg metformin
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Adolescent, Pre Diabetes
Effect of NNS on Metformin/GDF15, Pilot
Metformin use for diabetes has the benefit of causing weight loss in some. The investigators in a preclinical trial, demonstrated that mice consuming non-nutritive sweetened (NNS) drinks had worse glucose improvements and weight…
- Trial name
- NCT05400863
- Testing
- avoid sugary and NNS drinks plus start Metformin, avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2
Response To Oral Agents in Diabetes (ROAD)- Pilot Study
This proposal is to fund a pilot study to assess feasibility and refine methodology for an intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD).
- Trial name
- ROAD (NCT00780715)
- Testing
- Gliclazide MR, Sitagliptin, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University of Dundee
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61…
- Trial name
- ACHIEVE-3 (NCT06045221)
- Testing
- Orforglipron, Semaglutide
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,698 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2, Hyperglycemia
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Saxagliptin + Metformin XR (S+M) will be effective in stabilizing blood glucose (BG) levels in patients with newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia (BG levels 300 to 450 mg/dl) and glucose toxicity and…
- Trial name
- NCT01267448
- Testing
- Glipizide XL, Saxagliptin + Metformin XR, Metformin XR
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cook County Health
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Medically Reproducing Bariatric Surgery
Type 2 diabetes (DM2) is a chronic disease affecting 29 million Americans and a leading cause of blindness, kidney failure, and limb loss (Engelgau et al 2004).
- Trial name
- MRB (NCT03225209)
- Testing
- OPTIFAST
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Moahad S Dar
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients
The study will assess the total testosterone and sex hormone-binding globulin levels in men with type 2 diabetes before and after continuous subcutaneous insulin infusion and hypoglycemic drugs treatment.
- Trial name
- NCT03982238
- Testing
- Insulin, Metformin, Dapagliflozin
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Majianhua
Type 2 Diabetes Mellitus
Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly
Cognitive disorders increase with age and in the presence of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). In addition, digestive disorders, changes in dietary pattern and decreased activity negatively influence the…
- Trial name
- SmartAge (NCT04841668)
- Testing
- Metformin
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Apoptotic Signal Pathways in Endometrial Hyperplasia
Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
The purpose of the study is to determine apoptotic signaling pathways such as Survivin, Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial hyperplasia after metformin and…
- Trial name
- NCT02872818
- Testing
- 17β estradiol hemihydrate, Metformin, medroxyprogesterone acetate
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Kayseri Education and Research Hospital
Healthy
Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects
To investigate bioavailability of BI 187004 and of metformin after concomitant multiple oral administration of 240 mg BI 187004 q.d. and 1000 mg metformin b.i.d. in comparison to BI 187004 and metformin given alone.
- Trial name
- NCT02109679
- Testing
- metformin, BI 187004
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes.
- Trial name
- REALYSE (NCT05035082)
- Testing
- semaglutide, oral glucose-lowering medications (commercially available)
- Where
- 25 sites in United States
- Volunteers
- 1,018 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Coronary Artery Disease, Diabetes Mellitus, Type 2
Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD
The aim of this study is to evaluate the effect of adding Vildagliptin versus Glimepiride to Metformin on markers of inflammation, thrombosis, and atherosclerosis in diabetic patients with symptomatic Coronary artery diseases.
- Trial name
- NCT03693560
- Testing
- Vildagliptin 50 mg Oral Tablet, Metformin 1000 mg Oral Tablet, Glimepiride upto 4 mg Oral Tablet
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Damanhour University
Gestational Diabetes
Late Metabolic Effects of Metformin Therapy in Gestational Diabetes
Metformin in widely used as the treatment of gestational diabetes. However, it is not known whether exposure to metformin in utero has late metabolic effects on the child.
- Trial name
- DIARA2 (NCT02417090)
- Testing
- Insulin, Metformin
- Volunteers
- 173 people
- Sponsor
- Turku University Hospital
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug…
- Trial name
- NCT00099892
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.